sofosbuvir has been researched along with Hyperlipoproteinemia Type II in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bruckert, E; Caron, J; Dubart-Kupperschmitt, A; Fourrier, A; Gómez-Lechón, MJ; Heslan, JM; Luce, E; Nguyen, TH; Pène, V; Rosenberg, AR; Saheb, S; Tolosa, L; Villaret, M; Weber, A | 1 |
1 other study(ies) available for sofosbuvir and Hyperlipoproteinemia Type II
Article | Year |
---|---|
Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
Topics: Antiviral Agents; Apolipoprotein A-II; Cell Differentiation; Cholesterol; CRISPR-Cas Systems; Gene Editing; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Hyperlipoproteinemia Type II; Induced Pluripotent Stem Cells; Phenotype; Plasmids; Promoter Regions, Genetic; Proprotein Convertase 9; Receptors, LDL; Sofosbuvir; Sterol Regulatory Element Binding Protein 2 | 2019 |